Adcetris
brentuximab vedotin · CD30Three xenograft models from human HL and ALCL cell lines
Trodelvy: animal efficacy model or human cells?
sacituzumab govitecan · Trop-2
Efficacy evidence
Mouse xenografts bearing human Trop-2-expressing tumours
“Primary pharmacology was tested in murine xenograft models bearing human Trop-2 expressing tumors.”
Why that model
hRS7 does not bind mouse or rat Trop-2 despite ~80% homology
“Despite approx. 80% sequence homology at the protein level between human and rodent Trop-2, hRS7 did not bind to mouse and rat Trop-2.”
Reviewer's view of the efficacy data
EMA: adequate pharmacodynamic data; ADC inhibits Trop-2-positive tumour growth in vitro and in mouse xenografts
“The applicant has presented adequate non-clinical data which characterise the pharmacodynamic properties of sacituzumab govitecan. These data were presented in research study reports and in form of publications from the group in scientific journals. The ADC inhibits growth of Trop-2-positive tumour cells, including TNBC cells, in vitro as well as in xenograft transplant models in mice.”
Same question, other ADCs
Besponsa
inotuzumab ozogamicin · CD22Subcutaneous xenograft and systemically disseminated ALL mouse models
Datroway
datopotamab deruxtecan · Trop-2Nude mouse xenografts of human pancreatic cancer, NSCLC and breast cancer
Decnupaz
pivekimab sunirine · CD123Two BPDCN patient-derived xenograft (PDX) models in NSG mice
Elahere
mirvetuximab soravtansine · FRαOvarian cancer xenograft mouse models (single IV dose)
Emrelis
telisotuzumab vedotin · c-Metc-Met-positive NSCLC cell line-derived and patient-derived xenograft mouse models
Enhertu
fam-trastuzumab deruxtecan · HER2HER2-positive breast cancer xenograft mouse models (e.g., KPL-4 in nude mice)
Kadcyla
ado-trastuzumab emtansine · HER2HER2+ xenografts (BT-474 EI, Calu-3) and MMTV-HER2 transgenic tumor model; growth inhibition in all three at 3 to 31 mg/kg
Mylotarg
gemtuzumab ozogamicin · CD33CD33+ HL-60 leukemia xenograft in mice: >80% tumor growth inhibition
Padcev
enfortumab vedotin · Nectin-4Nectin-4-expressing patient-derived bladder cancer xenografts (AG-B1, AG-B8) in mice: >75% tumor growth inhibition
Polivy
polatuzumab vedotin · CD79bHuman DLBCL and B-cell lymphoma xenografts in mice; in vitro Ramos cytotoxicity
Tivdak
tisotumab vedotin · Tissue factorCervical cancer patient-derived xenograft (PDX) models in mice
Zynlonta
loncastuximab tesirine · CD19CD19-positive human Burkitt lymphoma (Ramos, Daudi) and DLBCL (WSU-DLCL2) xenografts in immunodeficient mice